APOC3 - 埼玉医科大学総合医療センター 内分泌・糖尿病内科

Journal Club
TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J,
Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K,
Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O,
Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL,
Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N,
Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F,
Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins
H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P,
Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP,
Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S.
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
N Engl J Med. 2014 Jul 3;371(1):22-31.
Jørgensen AB1, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A.
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
N Engl J Med. 2014 Jul 3;371(1):32-41.
2014年7月10日 8:30-8:55
8階 医局
埼玉医科大学 総合医療センター 内分泌・糖尿病内科
Department of Endocrinology and Diabetes,
Saitama Medical Center, Saitama Medical University
松田 昌文
Matsuda, Masafumi
APOC3 inhibits lipoprotein
lipase and hepatic lipase; it
is thought to inhibit
hepatic uptake[3] of
triglyceride-rich particles.
The APOA1, APOC3 and
APOA4 genes are closely
linked in both rat and
human genomes. The A-I
and A-IV genes are
transcribed from the same
strand, while the A-1 and
C-III genes are
convergently transcribed.
An increase in apoC-III
levels induces the
development of
Recent evidences suggest
an intracellular role for
Apo-CIII in promoting the
assembly and secretion of
triglyceride-rich VLDL
particles from hepatic cells
under lipid-rich conditions.
[4] However, two naturally
occurring point mutations
in human apoC3 coding
sequence, namely
Ala23Thr and Lys58Glu
have been shown to
abolish the intracellular
assembly and secretion of
triglyceride-rich VLDL
particles from hepatic
cells.[5] [6]
the Department of Biostatistics, Bioinformatics, and Systems Biology, University of Texas Graduate School of Biomedical Sciences at Houston (J.C.), the Human Genetics Center, University of Texas Health
Science Center at Houston (J.C., E.B.), Baylor College of Medicine (C.M.B., E.B.), and Methodist DeBakey Heart and Vascular Center (C.M.B.) — all in Houston; the Center for Human Genetic Research and
Cardiovascular Research Center, Massachusetts General Hospital (G.M.P., R.D., D. Altshuler, S. Kathiresan), the Department of Medicine, Harvard Medical School (G.M.P., R.D., D. Altshuler, S. Kathiresan), Merck
Sharp & Dohme (W.Y., D.R.), Nutrition and Genomics Laboratory, Jean Mayer–USDA Human Nutrition Research Center on Aging at Tufts University (J.M.O.), and Department of Biostatistics, Boston University
School of Public Health (L.A.C.) — all in Boston; the Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (G.M.P., R.D., D.N.F., M.D., N.G., D. Altshuler, S.G., S. Kathiresan); the School of
Public Health, University of Wisconsin–Milwaukee, Milwaukee (P.L.A.); the Departments of Genome Sciences (D.R.C., D.A.N., G.P.J.), Medicine (Medical Genetics) (D.R.C., G.P.J.), and Epidemiology (A.P.R.) and
the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services (B.M.P.), University of Washington, the Group Health Research Institute, Group Health Cooperative (B.M.P.),
and the Public Health Sciences Division, Fred Hutchinson Cancer Research Center (C.K., A.P.R.) — all in Seattle; the Cardiovascular Division, Department of Medicine, and the Division of Statistical Genomics,
Washington University School of Medicine, St. Louis (N.O.S.); the Departments of Genetics (L.A.L.), Biostatistics (Z.T., D.-Y.L.), and Epidemiology (N.F., K.E.N.) and the Carolina Center for Genome Sciences
(K.E.N.), University of North Carolina, Chapel Hill; the Charles Bronfman Institute for Personalized Medicine (Y.L., O.G., E.P.B., R.J.F.L.) and the Mindich Child Health and Development Institute (R.J.F.L.), Icahn
School of Medicine at Mount Sinai, New York; the Departments of Internal Medicine (H.Z., E.S., C.J.W.), Computational Medicine and Bioinformatics (H.Z., C.X., E.S., C.J.W.), Human Genetics (H.Z., C.J.W.), and
Biostatistics (G.J., Y.H., H.M.K., G.A.), the Division of Gastroenterology (E.S.), and the Center for Statistical Genetics (G.A.), University of Michigan, Ann Arbor; the Department of Clinical Sciences, Clinical
Research Center (G.H., M.O.-M.), Department of Clinical Science, Genetic and Molecular Epidemiology Unit (S.A.E.), and Department of Clinical Sciences, Diabetes and Endocrinology (O.M.), Lund University and
University Hospital Malmö, Malmö, the Department of Medicine, Skellefteå Hospital, Skellefteå (J.-H.J.), and the Department of Public Health and Clinical Medicine, Umeå University, Umeå, (J.-H.J.) — all in
Sweden; the Department of Cardiovascular Sciences, University of Leicester, and National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, Leicester (N. Masca, N.J.S.), the
William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London (K.S., S. Kanoni, P.D.), the Division of Cardiovascular Medicine, Radcliffe
Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford (A.G., M.F., H.W.), the Medical Research Institute, Ninewells Hospital and Medical School, Dundee (N.V.Z.,
C.N.A.P.), the Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital (N.W., L.A.C.), and Wellcome Trust Sanger Institute (P.D.), Cambridge, and the Division of
Epidemiology, School of Medicine, University of Leeds, Leeds (A.S.H.) — all in the United Kingdom; the Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano (S.D.,
R.A.) and the Division of Cardiology, Ospedale Niguarda (P.A.M.), Milan, the University of Verona School of Medicine, Department of Medicine, Verona (D.G., O.O., N. Martinelli), and the Division of Cardiology,
Azienda Ospedaliero-Universitaria di Parma, Parma (D. Ardissino) — all in Italy; the National Heart, Lung and Blood Institute Framingham Heart Study (C.S.F., C.J.O.) and the Center for Population Studies (C.S.F.),
Framingham, MA; the Nord-Trøndelag Health Study (HUNT) Research Center, Department of Public Health and General Practice, Norwegian University of Science and Technology (K.H., O.L.H.), and Levanger
Hospital (K.H.), Levanger, and St. Olav Hospital, Trondheim University Hospital, Trondheim (O.L.H.) — both in Norway; the Division of Cardiology, University of Ottawa Heart Institute, Ottawa (M. Nikpay, R.M.);
the Department of Medicine, Stanford University School of Medicine, Stanford, CA (T.L.A.); the Departments of Epidemiology and Medicine, College of Public Health, University of Iowa, Ames (J.R.); the Division
of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC (L.W.M.); Deutsches Herzzentrum München (W.K., H.S.), Medizinische Klinik, Klinikum rechts der Isar
(W.K.), and Institute of Human Genetics (T.M.), Technische Universität München, and the German Center for Cardiovascular Research (W.K., A.P.), Munich, Helmholtz Zentrum München, German Research Center
for Environmental Health, Institute of Epidemiology II, Neuherberg (A.P.), Institute of Epidemiology and Biobank popgen, Christian-Albrechts University Kiel, Kiel (W.L.), Department of Cardiology, West German
Heart Center, Essen (R.E.), Institut für Medizinische Biometrie und Statistik (I.R.K., J.K.) and Institut für Integrative und Experimentelle Genomik (J.E.), Universität zu Lübeck, Universitätsklinikum SchleswigHolstein (I.R.K., J.K.), and DZHK (German Research Center for Cardiovascular Research) (J.E.), Lübeck, and the Institute of Human Genetics, University of Bonn, Bonn (F.D.) — all in Germany; the Department of
Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Investigation, and Instituto Madrileño de Estudios Avanzados–Alimentacion, Madrid (J.M.O.); King Abdulaziz University,
Jeddah, Saudi Arabia (P.D.); the Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson (J.G.W.); the Center for Public Health Genomics, University of Virginia,
Charlottesville (S.S.R.); and the Departments of Pathology and Biochemistry, University of Vermont College of Medicine, Burlington (R.P.T.).
Plasma triglyceride levels are heritable and are
correlated with the risk of coronary heart disease.
Sequencing of the protein-coding regions of the
human genome (the exome) has the potential to
identify rare mutations that have a large effect on
We sequenced the protein-coding regions of
18,666 genes in each of 3734 participants of
European or African ancestry in the Exome
Sequencing Project. We conducted tests to
determine whether rare mutations in coding
sequence, individually or in aggregate within a
gene, were associated with plasma triglyceride
levels. For mutations associated with triglyceride
levels, we subsequently evaluated their
association with the risk of coronary heart
disease in 110,970 persons.
Figure 2. Association of APOC3 Loss-of-Function Mutations with Risk of Coronary Heart Disease among 110,970 Participants in 15 Studies. In each study, we tested the
association of loss-of-function carrier status (heterozygous for any of four mutations: APOC3 R19X, IVS2+1G→A, IVS3+1G→T, or A43T) with the risk of coronary heart disease.
We calculated P values for the association tests and confidence intervals for the odds ratios with the use of exact methods. We performed a meta-analysis with the use of the
Cochran–Mantel–Haenszel statistics for stratified 2-by-2 tables. The Cochran– Mantel–Haenszel method combines score statistics rather than Wald statistics and is particularly
useful when some observed odds ratios are zero. For each study, squares indicate the estimated odds ratios and the corresponding lines indicate the 95% confidence intervals.
The diamond indicates the combined estimate of the odds ratio and the corresponding 95% confidence interval. HA denotes Hispanic ancestry. The full study names are as
follows: ARIC Atherosclerosis Risk in Communities. ATVB Italian Atherosclerosis, Thrombosis, and Vascular Biology Study, EPIC European Prospective Study into Cancer and
Nutrition, FHS Framingham Heart Study, FIA3 First Myocardial Infarction, in AC County 3, GoDARTS Genetics of Diabetes Audit and Research Tayside Study, HUNT Nord–
Trøndelag Health Study, IPM Mt. Sinai Institute for Personalized Medicine Biobank, MDC–CVA Malmö Diet and Cancer Study Cardiovascular Cohort, OHS Ottawa Heart Study,
PROCARDIS, Precocious Coronary Artery Disease Study, VHS Verona Heart Study, WHI Women’s Health Initiative, and WTCCC Wellcome Trust Case Control Consortium. All
15 studies are described in Table S3 in the Supplementary Appendix.
Figure 3. Cumulative Probability of Freedom from Coronary Heart Disease (CHD) According
to Plasma Level of APOC3 at Baseline in the Framingham Heart Study.
Plasma APOC3 levels were 14.2 mg per deciliter or less in the lowest third of the population, 14.3
to 17.9 mg per deciliter in the middle third, and 18.0 mg per deciliter or more in the highest third.
Median follow-up was 14.4 years. The numbers in parentheses are the numbers of study
participants who were undergoing follow-up at the specified time points.
An aggregate of rare mutations in the gene encoding
apolipoprotein C3 (APOC3) was associated with lower
plasma triglyceride levels. Among the four mutations that
drove this result, three were loss-of-function mutations: a
nonsense mutation (R19X) and two splice-site mutations
(IVS2+1G→A and IVS3+1G→T). The fourth was a missense
mutation (A43T). Approximately 1 in 150 persons in the study
was a heterozygous carrier of at least one of these four
mutations. Triglyceride levels in the carriers were 39% lower
than levels in noncarriers (P<1×10−20), and circulating levels
of APOC3 in carriers were 46% lower than levels in
noncarriers (P=8×10−10). The risk of coronary heart disease
among 498 carriers of any rare APOC3 mutation was 40%
lower than the risk among 110,472 noncarriers (odds ratio,
0.60; 95% confidence interval, 0.47 to 0.75; P=4×10−6).
Rare mutations that disrupt APOC3 function were
associated with lower levels of plasma
triglycerides and APOC3. Carriers of these
mutations were found to have a reduced risk of
coronary heart disease.
(Funded by the National Heart, Lung, and Blood
Institute and others.)
Copenhagen University Hospital and Faculty of Health and Medical Sciences,
University of Copenhagen (A.B.J., R.F.-S., B.G.N., A.T.-H.), the Department of
Clinical Biochemistry, Rigshospitalet (A.B.J., R.F.-S., A.T.-H.), the Department of
Clinical Biochemistry (B.G.N.) and the Copenhagen General Population Study
(R.F.-S., B.G.N., A.T.-H.), Herlev Hospital, and the Copenhagen City Heart Study,
Frederiksberg Hospital (B.G.N., A.T.-H.)
High plasma levels of nonfasting triglycerides are
associated with an increased risk of ischemic
cardiovascular disease. Whether lifelong low levels
of nonfasting triglycerides owing to mutations in the
gene encoding apolipoprotein C3 (APOC3) are
associated with a reduced risk of ischemic
cardiovascular disease in the general population is
Using data from 75,725 participants in two generalpopulation studies, we first tested whether low levels
of nonfasting triglycerides were associated with
reduced risks of ischemic vascular disease and
ischemic heart disease. Second, we tested whether
loss-of-function mutations in APOC3, which were
associated with reduced levels of nonfasting
triglycerides, were also associated with reduced risks
of ischemic vascular disease and ischemic heart
disease. During follow-up, ischemic vascular disease
developed in 10,797 participants, and ischemic heart
disease developed in 7557 of these 10,797
Figure 3. Cumulative Incidences of Ischemic Vascular Disease and Ischemic
Heart Disease as a Function of Age and APOC3 Genotype.
Data are for all heterozygotes for the R19X, IVS2+1G→A, or A43T mutation versus
noncarriers of these mutations among participants in the CCHS and the CGPS
Participants with nonfasting triglyceride levels of less than 1.00
mmol per liter (90 mg per deciliter) had a significantly lower
incidence of cardiovascular disease than those with levels of 4.00
mmol per liter (350 mg per deciliter) or more (hazard ratio for
ischemic vascular disease, 0.43; 95% confidence interval [CI],
0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI,
0.31 to 0.52). Heterozygosity for loss-of-function mutations in
APOC3, as compared with no APOC3 mutations, was associated
with a mean reduction in nonfasting triglyceride levels of 44%
(P<0.001). The cumulative incidences of ischemic vascular
disease and ischemic heart disease were reduced in
heterozygotes as compared with noncarriers of APOC3 mutations
(P=0.009 and P=0.05, respectively), with corresponding risk
reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86;
P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99;
Loss-of-function mutations in APOC3 were
associated with low levels of triglycerides
and a reduced risk of ischemic
cardiovascular disease.
(Funded by the European Union and

similar documents